Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Insite Vision Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Ottoman who wrote (951)	7/7/1999 4:31:00 PM
From: bob zagorin	Respond to of 1060

InSite Vision Announces the Allowance and Issuance of Additional DuraSite Patents ALAMEDA, Calif.--(BW HealthWire)--July 7, 1999--InSite Vision Incorporated (AMEX:ISV) today announced the allowance and issuance of additional patents on its proprietary DuraSite(R) sustained release ophthalmic drug delivery system. These patents further enhance the proprietary position of the company's ISV-205 glaucoma treatment drug licensed to Pharmacia & Upjohn earlier this year. ISV-205 is the first drug to address the cause of glaucoma rather than the symptoms by blocking a TIGR gene produced protein, which causes intraocular hypertension. ISV-205 is a novel anti-glaucoma drug that was shown in a recent clinical study to be effective in blocking intraocular pressure rise caused by steroid use. Significantly, one of the new patents covers the whole class of non-steroidal anti-inflammatory drugs, which includes diclofenac the active ingredient of ISV-205. "Another patent allowance extends the pH and viscosity ranges specified in the original DuraSite patents permitting a much wider spectrum of drugs to be incorporated into the DuraSite delivery system," said Dr. S. Kumar Chandrasekaran, Chairman and Chief Executive Officer of InSite Vision. "This will enhance the ongoing strategic partnering program we initiated earlier this year which already has resulted in the Pharmacia & Upjohn licensing and equity investment agreement," Dr. Chandrasekaran continued. InSite Vision's proprietary sustained-release DuraSite technology increases the residence time of a drug formulation in the cul-de-sac of the eye resulting in higher concentrations and a longer residence time of the drug both on the surface, and inside, the eye. This press release contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of InSite Vision. Such statements entail a number of risks and uncertainties involving the results of preclinical and clinical studies and determinations by the U.S. Food and Drug Administration, as well as the Risk Factors listed from time to time in the company's SEC filings including, but not limited to, its Form 10-Q for the quarter ended March 31, 1999. CONTACT: InSite Vision Incorporated Sandra Heine, 510/865-8800 or Core Communications Group, Inc. Robert Ferri, 415/331-7003 San Francisco (IR) rferri@nextwavestocks.com Joshua Z. Levine, 516/487-8322 New York (IR) jzlevine@nextwavestocks.com